NCT01006785View on ClinicalTrials.gov

Efficacy and Safety of DLBS1425 in Subjects With Advanced/Metastatic Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Breast Cancer
Interventions
DRUG

DLBS1425

3 X 150 mg daily for 12 - 16 weeks of treatment

DRUG

DLBS1425

3 X 300 mg daily for 12 - 16 weeks of treatment

Trial Locations (3)

40161

Dr. Hasan Sadikin Hospital, Department of Internal Medicine, Bandung

55284

Dr. Sardjito Hospital, Department of Internal Medicine, Yogyakarta

Unknown

Dr. Cipto Mangunkusumo Hospital, Division of Medical Haematology and Oncology, Jakarta

Sponsors

Lead Sponsor

Dexa Medica Group
All Listed Sponsors
lead

Dexa Medica Group

INDUSTRY

NCT01006785 - Efficacy and Safety of DLBS1425 in Subjects With Advanced/Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter